#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac

• https://x.com/Yuz6Yusof/status/2062886696459346275/photo/1

#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS

• https://x.com/Yuz6Yusof/status/2062878356006166772/photo/1

Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6

• https://x.com/RHEUMarampa/status/2062880273088332213/photo/1
• https://x.com/RHEUMarampa/status/2062880273088332213/photo/1

Rapcabtagene Autoleucel -YTB323 rapidly manufactured CD19 CAR T #POS0303 #EULAR2026 @RheumNow 24 months follow up data for 21 pts. Durable b cell reduction and decrease in disease activity. https://t.co/m3lYjZJJIy

• https://x.com/bella_mehta/status/2062869476110987634/photo/1
• https://x.com/bella_mehta/status/2062869476110987634/photo/1
• https://x.com/bella_mehta/status/2062869476110987634/photo/1

#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC

• https://x.com/DrMiniDey/status/2062865769390625081/photo/1

#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow

#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5

• https://x.com/Yuz6Yusof/status/2062849640374890515/photo/1

Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA? Yes: faster remission at week 4 (84.6% vs 15%) But: equal at week 24 Prospective study in 46 patients #POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0

• https://x.com/Nellziade/status/2062849233623908374/photo/1

What do you think about this cartoon-style format for posters? A- I love it! B- It’s Ok but I prefer classic As for the content: Axia digital therapeutic app improves mobility, BASDAI, sleep an sexual function in 32 patients #POS0199 #EULAR2026 @rheumnow https://t.co/mV83dMF4vi

• https://x.com/Nellziade/status/2062847138959081686/photo/1

#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit

• https://x.com/Yuz6Yusof/status/2062846673345233231/photo/1

#EULAR2026 OP0340 WK84 data of single arm Phase 2 Daratumumab (CD38 plasma depleter) weekly for 8 doses with background IS in N=10 #SLE: rapid reduction of antidsDNA & efficacy. 6/10 relapsed from WK20; 5/10 had low IgG and needed IVIG. Promising but Not so durable @RheumNow https://t.co/UrTywqkQ4F

• https://x.com/Yuz6Yusof/status/2062840252742471836/photo/1

Understanding how Bispecific T cell engagers work: remarkable mode of action! Let’s hope it works as well as in oncology! #teclistamab in #SSc #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/waSCXKA79Y

• https://x.com/Nellziade/status/2062824614451884035/photo/1
• https://x.com/Nellziade/status/2062824614451884035/photo/1

#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw

• https://x.com/Yuz6Yusof/status/2062823915534123181/photo/1